These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 27609792

  • 1. Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.
    Jani AB, Schreibmann E, Rossi PJ, Shelton J, Godette K, Nieh P, Master VA, Kucuk O, Goodman M, Halkar R, Cooper S, Chen Z, Schuster DM.
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [Abstract] [Full Text] [Related]

  • 2. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB.
    Int J Radiat Oncol Biol Phys; 2016 Sep 01; 96(1):206-13. PubMed ID: 27511856
    [Abstract] [Full Text] [Related]

  • 3. Anatomic variations due to radical prostatectomy. Impact on target volume definition and dose-volume parameters of rectum and bladder.
    Sanguineti G, Castellone P, Foppiano F, Franzone P, Marcenaro M, Tognoni P, Bolognesi A, Ceresoli GL, Fiorino C.
    Strahlenther Onkol; 2004 Sep 01; 180(9):563-72. PubMed ID: 15378187
    [Abstract] [Full Text] [Related]

  • 4. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance.
    Abiodun-Ojo OA, Jani AB, Akintayo AA, Akin-Akintayo OO, Odewole OA, Tade FI, Joshi SS, Master VA, Fielder B, Halkar RK, Zhang C, Goyal S, Goodman MM, Schuster DM.
    J Nucl Med; 2021 Aug 01; 62(8):1089-1096. PubMed ID: 33517323
    [Abstract] [Full Text] [Related]

  • 5. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
    Akin-Akintayo OO, Jani AB, Odewole O, Tade FI, Nieh PT, Master VA, Bellamy LM, Halkar RK, Zhang C, Chen Z, Goodman MM, Schuster DM.
    Clin Nucl Med; 2017 Jan 01; 42(1):e22-e28. PubMed ID: 27749412
    [Abstract] [Full Text] [Related]

  • 6. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography-Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects.
    Dhere VR, Schuster DM, Goyal S, Schreibmann E, Hershatter BW, Rossi PJ, Shelton JW, Patel PR, Jani AB.
    Int J Radiat Oncol Biol Phys; 2022 Aug 01; 113(5):1003-1014. PubMed ID: 35417762
    [Abstract] [Full Text] [Related]

  • 7. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
    Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ, Shelton JW, Patel PR, Xu KM, Goodman M, Master VA, Joshi SS, Kucuk O, Carthon BC, Bilen MA, Abiodun-Ojo OA, Akintayo AA, Dhere VR, Schuster DM.
    Lancet; 2021 May 22; 397(10288):1895-1904. PubMed ID: 33971152
    [Abstract] [Full Text] [Related]

  • 8. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S, Mathai M, Cui J, Purdy JA, Valicenti RK.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):1897-902. PubMed ID: 21536391
    [Abstract] [Full Text] [Related]

  • 9. Do differences in target volume definition in prostate cancer lead to clinically relevant differences in normal tissue toxicity?
    Livsey JE, Wylie JP, Swindell R, Khoo VS, Cowan RA, Logue JP.
    Int J Radiat Oncol Biol Phys; 2004 Nov 15; 60(4):1076-81. PubMed ID: 15519777
    [Abstract] [Full Text] [Related]

  • 10. Utility of 18F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study.
    Galgano SJ, McDonald AM, Rais-Bahrami S, Porter KK, Choudhary G, Burgan C, Bhambhvani P, Nix JW, Morgan DE, Li Y, Thomas JV, McConathy J.
    AJR Am J Roentgenol; 2021 Sep 15; 217(3):720-729. PubMed ID: 33052718
    [Abstract] [Full Text] [Related]

  • 11. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
    Wahart A, Guy JB, Vallard A, Geissler B, Ben Mrad M, Falk AT, Prevot N, de Laroche G, Rancoule C, Chargari C, Magné N.
    Br J Radiol; 2016 Sep 15; 89(1058):20150579. PubMed ID: 26648528
    [Abstract] [Full Text] [Related]

  • 12. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S, Dubray B, Modzelewski R, Bohn P, Hapdey S, Vincent S, Anger E, Gensanne D, Pirault N, Pierrick G, Vera P.
    Radiat Oncol; 2018 Oct 23; 13(1):208. PubMed ID: 30352608
    [Abstract] [Full Text] [Related]

  • 13. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.
    Kim EH, Siegel BA, Teoh EJ, Andriole GL, LOCATE Study Group.
    Urol Oncol; 2021 Jun 23; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Postprostatectomy target-normal structure overlap volume differences using computed tomography and radioimmunoscintigraphy images for radiotherapy treatment planning.
    Su A, Blend MJ, Spelbring D, Hamilton RJ, Jani AB.
    Clin Nucl Med; 2006 Mar 23; 31(3):139-44. PubMed ID: 16495731
    [Abstract] [Full Text] [Related]

  • 16. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy.
    Jani AB, Spelbring D, Hamilton R, Blend MJ, Pelizzari C, Brendler C, Krauz L, Vijayakumar S, Sapra B, Weichselbaum RR.
    J Nucl Med; 2004 Feb 23; 45(2):238-46. PubMed ID: 14960642
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM.
    Eur J Nucl Med Mol Imaging; 2016 Sep 23; 43(10):1773-83. PubMed ID: 27091135
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy.
    Payne H, Bomanji J, Bottomley D, Scarsbrook AF, Teoh EJ, FALCON study group.
    Nucl Med Commun; 2022 Feb 01; 43(2):201-211. PubMed ID: 34669678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.